The year 1992 witnessed the culmination and reporting of a number of landmark clinical
trials in congestive heart failure. These trials have provided further data in support of the use …

Background Candesartan, Valsartan and Losartan are Angiotensin Receptor Blockers
(ARBs) recommended in heart failure (HF) treatment guidelines, yet studies suggest …

Background: Patients with heart failure (HF) and preserved left ventricular ejection fraction
comprise a heterogeneous group including some with mildly reduced EF. We hypothesized …

Understanding of the pathophysiology of heart failure has advanced over the last decade,
resulting in new therapeutic advances. Convincing data exist that angiotensin-converting …

Angiotensin converting enzyme (ACE) inhibitors are the only therapeutic agents used in the
treatment of chronic heart failure that have been shown to both improve symptoms and …

In patients with moderate to severe CHF, enalapril improves symptoms and is well tolerated.
It increases functional capacity in the form of exercise time and reduces the left ventricular …

Congestive heart failure has emerged as an important public health problem world wide. It is
the single most common cause for hospitalization of patients over the age of 65 years in the …

Heart failure is a major health problem and its prevalence is growing, primarily as a
consequence of the aging of the population. Recently, we have witnessed significant …

Congestive heart failure is a syndrome common in the United States, especially in elderly
patients. The most common etiology is coronary artery disease. A number of general factors …